Ken Griffin Y M Abs Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$9.95 - $15.39 $994 - $1,539	100 Added 33.33%	400 $5,000
Q2 2024 Aug 14, 2024	SELL	$11.6 - $17.25 $242,440 - $360,525	-20,900 Reduced 98.58%	300 $3,000
Q1 2024 May 15, 2024	BUY	$6.57 - $18.69 $124,173 - $353,241	18,900 Added 821.74%	21,200 $344,000
Q4 2023 Feb 14, 2024	BUY	$4.88 - $7.42 $11,224 - $17,066	2,300 New	2,300 $15,000
Q2 2023 Aug 14, 2023	BUY	$5.68 - $10.34 $6,816 - $12,408	1,200 Added 300.0%	1,600 $10,000
Q1 2023 May 15, 2023	BUY	$2.83 - $5.11 $1,132 - $2,044	400 New	400 $2,000

112

27.1M

40.3K

400

Ticker YMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,719,500
Market Cap $270M
Description
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.